Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in people with HIV on suppressive antiretroviral therapy
2023-000061-14Phase 2Active
- Sponsor
- Germans Trias i Pujol Research Institute
- Start
- Feb 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in human immunodeficiency virus infection (HIV), sponsored by Germans Trias i Pujol Research Institute. Primary endpoint: Grade 3 or 4 treatment-related adverse events or laboratory abnormalities. Started Feb 2023; status: active.
02
Drugs
dasatinib
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2023-000061-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-000061-14.